Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Becomes first Japanese logistics company to collaborate with EMBALL’ISO, which has a proven track record in vaccine transport
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Ex-Azithromycin has shown a growth of 8% and 14% in April 2022 and May 2022 respectively
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
Brings 25 years of global operations and supply chain experience to Piramal
Subscribe To Our Newsletter & Stay Updated